Here's Why Philip Morris Raises Its 2025 EPS Guidance Again

Philip Morris (PM) has once again raised its 2025 adjusted EPS guidance to $7.43-$7.56, driven by a robust Q2 performance largely attributed to its smoke-free portfolio. This segment, featuring IQOS and ZYN, saw gross profit jump over 23% and now accounts for 42% of PM's total gross profit, contributing to a 16.1% increase in adjusted operating income. The raised outlook signals management's confidence in the sustainable growth of its multi-category smoke-free strategy, despite PM shares declining 10.2% in the past month and trading at a premium P/E of 20.16x compared to the industry average.

Analysis

Philip Morris has upgraded its full-year 2025 adjusted EPS guidance to a range of $7.43-$7.56, reflecting management's increased confidence following a strong second quarter. This optimism is anchored in the rapid expansion of its smoke-free portfolio, where gross profit surged by over 23% and now accounts for 42% of the company's total gross profit. The segment's net revenues grew 15.2%, driven by an 11.4% rise in IQOS heated tobacco unit sales and a significant rebound in ZYN's U.S. consumer offtake, which grew 26%. Critically, the company demonstrated significant operating leverage, with adjusted operating income growing 16.1%, outpacing revenue gains due to favorable pricing, scale efficiencies, and the mix-shift towards higher-margin smoke-free products. Despite these robust fundamentals and a positive earnings outlook for 2025 and 2026 (projected growth of 14.2% and 11.9% respectively), the stock has declined 10.2% over the past month and trades at a premium forward P/E of 20.16x, well above the industry average of 14.67x, creating a divergence between recent performance and operational results.

Key Decisions for Investors

• The recent 10.2% share price decline, juxtaposed with a raised EPS guidance and strong smoke-free segment growth, may present a strategic entry point for investors confident in the company's long-term transition.
• Investors must consider if the premium valuation, with a forward P/E of 20.16x, is justified by the company's superior margin expansion and forecasted double-digit earnings growth compared to the broader industry.
• Continue to monitor the market share and sales velocity of IQOS and ZYN, as their sustained performance is crucial for validating the company's growth narrative and defending its market position against intensifying competition from Altria and Turning Point Brands.